ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för trametinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

35 träffar

Bibliografisk träff 2021-11-09

BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.

Li J, Wang Q, Ge J, Tian Y, Yao W.

Oncologist · research-article; journal article; case reports · DOI 10.1002/onco.13979

Bibliografisk träff 2021-10-01

MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models.

Gong X, Fan L, Wang P.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000001092

Bibliografisk träff 2021-10-01

Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer.

Okano N, Mizutani T, Nagashima F, Furuse J.

Lancet Oncol · letter; comment · DOI 10.1016/s1470-2045(21)00489-7

Bibliografisk träff 2021-09-14

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.

Thawer A, Miller WH, Gregorio N, Claveau J, Rajagopal S, Savage KJ, Song X, Petrella TM, On Behalf Of The Canadian Working Group.

Curr Oncol · other; research support, non-u.s. gov't; consensus statement; journal article · DOI 10.3390/curroncol28050304

Bibliografisk träff 2021-08-30

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.

Ota T, Okabayashi A, Fukuoka M.

Respirol Case Rep · journal article; case reports; case-report · DOI 10.1002/rcr2.841

Bibliografisk träff 2021-08-19

Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma.

Lee CS, Miao E, Das K, Seetharamu N.

BMJ Case Rep · journal article; case reports; case-report · DOI 10.1136/bcr-2021-243264

Bibliografisk träff 2021-08-09

KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.

Homayun-Sepehr N, McCarter AL, Helaers R, Galant C, Boon LM, Brouillard P, Vikkula M, Dellinger MT.

JCI Insight · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.149831

Bibliografisk träff 2021-08-06

Trametinib enhances ATRA-induced differentiation in AML cells.

Lu H, Li ZY, Ding M, Liang C, Weng XQ, Sheng Y, Wu J, Cai X.

Leuk Lymphoma · research support, non-u.s. gov't; journal article · DOI 10.1080/10428194.2021.1961231

Bibliografisk träff 2021-07-25

Rapamycin and trametinib: a rational combination for treatment of NSCLC.

Sun CY, Li YZ, Cao D, Zhou YF, Zhang MY, Wang HY.

Int J Biol Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/ijbs.62752

Bibliografisk träff 2021-07-22

Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.

Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.15035

Bibliografisk träff 2021-05-26

Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.

Elbadawy M, Sato Y, Mori T, Goto Y, Hayashi K, Yamanaka M, Azakami D, Uchide T, Fukushima R, Yoshida T, Shibutani M, Kobayashi M, Shinohara Y, Abugomaa A, Kaneda M, Yamawaki H, Usui T, Sasaki K.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1080/15384047.2021.1919004

Bibliografisk träff 2021-04-22

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.

Tudor DV, Bâldea I, Olteanu DE, Fischer-Fodor E, Piroska V, Lupu M, Călinici T, Decea RM, Filip GA.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22094387

Bibliografisk träff 2015-06-25

The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity.

Slack C, Alic N, Foley A, Cabecinha M, Hoddinott MP, Partridge L.

Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cell.2015.06.023

Bibliografisk träff 2013-09-19

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL.

Cell Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.celrep.2013.08.023

Bibliografisk träff 2013-08-23

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.

Ho MY, Morris MJ, Pirhalla JL, Bauman JW, Pendry CB, Orford KW, Morrison RA, Cox DS.

Xenobiotica · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.3109/00498254.2013.831143

Bibliografisk träff 2013-08-01

Trametinib for the treatment of melanoma.

Alluri N, Jimeno A.

Drugs Today (Barc) · journal article · DOI 10.1358/dot.2013.49.8.1990151

Bibliografisk träff 2013-07-25

Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.

Cox DS, Papadopoulos K, Fang L, Bauman J, LoRusso P, Tolcher A, Patnaik A, Pendry C, Orford K, Ouellet D.

J Clin Pharmacol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/jcph.115

Bibliografisk träff 2013-07-03

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0067583

Bibliografisk träff 2013-07-01

Trametinib: first global approval.

Wright CJ, McCormack PL.

Drugs · journal article · DOI 10.1007/s40265-013-0096-1

Bibliografisk träff 2013-06-01

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.

Lemech C, Infante J, Arkenau HT.

Drugs · journal article · DOI 10.1007/s40265-013-0049-8

Bibliografisk träff 2013-06-01

Dabrafenib in the treatment of advanced melanoma.

Medina T, Amaria MN, Jimeno A.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2013.49.6.1968669

Bibliografisk träff 2013-05-24

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1634/theoncologist.2012-0391

Bibliografisk träff 2013-05-08

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.

Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, Shelling AN, Baguley BC.

Front Genet · research-article; journal article · DOI 10.3389/fgene.2013.00066

Bibliografisk träff 2013-04-12

MEK and the inhibitors: from bench to bedside.

Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/1756-8722-6-27

Bibliografisk träff 2013-04-11

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.

Infante JR, Papadopoulos KP, Bendell JC, Patnaik A, Burris HA, Rasco D, Jones SF, Smith L, Cox DS, Durante M, Bellew KM, Park JJ, Le NT, Tolcher AW.

Eur J Cancer · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.ejca.2013.03.020

Bibliografisk träff 2013-04-03

Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.

Watanabe M, Sowa Y, Yogosawa M, Sakai T.

Cancer Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cas.12139

Bibliografisk träff 2013-02-24

Latest approved therapies for metastatic melanoma: what comes next?

Menaa F.

J Skin Cancer · research-article; journal article · DOI 10.1155/2013/735282

Bibliografisk träff 2013-02-23

Trametinib (GSK1120212) in the treatment of melanoma.

Salama AK, Kim KB.

Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2013.770475

Bibliografisk träff 2013-02-01

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, Gilmer TM, Parsons JT, Bauer TW.

Neoplasia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1593/neo.121712

Bibliografisk träff 2013-01-02

Resistance to BRAF-targeted therapy in melanoma.

Sullivan RJ, Flaherty KT.

Eur J Cancer · review; journal article · DOI 10.1016/j.ejca.2012.11.019